Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
A few GLP-1RAs, such as liraglutide and semaglutide, have been shown to effectively improve cardiovascular outcomes in patients with T2DM in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial, respectively [22,23]
2013 Jan;26(1):11-5
10.1038/s41398-017-0056-8 Transl Psychiatry
J Clin Endocrinol Metab 101(8):31553162
US$ 29.69
US$ 24.74
US$ 24.69
US$ 24.04
